A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)

NCT02240433 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: LY2157299
DRUG: Sorafenib

Sponsor

Eli Lilly and Company